Abramson JS et al. Pivotal safety and efficacy results from TRANSCEND NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed/refractory (R/R) large B cell lymphomas. ASH 2019;Abstract 241.
Abramson JS et al. Updated safety and long-term clinical outcomes in TRANSCEND NHL 001, a pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL. ASCO 2018;Abstract 7505.
Davids MS et al. Revised dose ramp-up to mitigate the risk of tumor lysis syndrome when initiating venetoclax in patients with mantle cell lymphoma. J Clin Oncol 2018;[Online ahead of print]. Abstract
Bartlett NL et al. Brentuximab vedotin with chemotherapy for stage 3/4 classical Hodgkin lymphoma (cHL): 4-year update of the Echelon-1 study. ASH 2019;Abstract 4026.
Connors JM et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma. N Engl J Med 2018;378(4):331-44. Abstract
Evens AM et al. Older patients (pts) with previously untreated classical Hodgkin lymphoma (cHL): A detailed analysis from the phase 3 ECHELON-1 Study. ASH 2018;Abstract 1618.
Eyre T et al. Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma post BTK inhibition therapy. EHA 2018;Abstract S855.
Fischer K et al. Quantitative analysis of minimal residual disease (MRD) shows high rates of undetectable MRD after fixed-duration chemotherapy-free treatment and serves as surrogate marker for progression-free survival: A prospective analysis of the randomized CLL14 Trial. ASH 2019;Abstract 36.
Fischer K et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med 2019;380(23):2225-36. Abstract
Ghia P et al. ASCEND phase 3 study of acalabrutinib vs investigator’s choice of rituximab plus idelalisib (IDR) or bendamustine (BR) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). EHA 2019;Abstract LB2606.
Handunnetti SM et al. Three year update of the phase II ABT-199 (venetoclax) and ibrutinib in mantle cell lymphoma (AIM) study. ASH 2019;Abstract 756.
Jain N et al. Combined ibrutinib and venetoclax for first-line treatment for patients with chronic lymphocytic leukemia (CLL). ASH 2019;Abstract 34.
Locke FL et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A single-arm, multicentre, phase 1-2 trial. Lancet Oncol 2019;20(1):31-42. Abstract
Moreno C et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): A multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2019;20(1):43-56. Abstract
Ramchandren R et al. Brentuximab vedotin plus chemotherapy in North American subjects with newly diagnosed stage III or IV Hodgkin lymphoma. Clin Cancer Res 2019;25(6):1718-26. Abstract
Ramchandren R et al. Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: Safety and efficacy in the phase II CheckMate 205 study. J Clin Oncol 2019;37(23):1997-2007. Abstract
Rule S et al. Long-term outcomes with ibrutinib versus the prior regimen: A pooled analysis in relapsed/refractory (R/R) mantle cell lymphoma (MCL) with up to 7.5 years of extended follow-up. ASH 2019;Abstract 1538.
Schuster SJ et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 2019;380(1):45-56. Abstract
Seymour JF et al. Four-year analysis of Murano study confirms sustained benefit of time-limited venetoclax-rituximab (VenR) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). ASH 2019;Abstract 355.
Shanafelt TD et al. Ibrutinib and rituximab provides superior clinical outcome compared to FCR in younger patients with chronic lymphocytic leukemia (CLL): Extended follow-up from the E1912 trial. ASH 2019;Abstract 33.
Shanafelt TD et al. A randomized phase III study of ibrutinib (PCI-32765)-based therapy vs. standard fludarabine, cyclophosphamide, and rituximab (FCR) chemoimmunotherapy in untreated younger patients with chronic lymphocytic leukemia (CLL): A trial of the ECOG-ACRIN Cancer Research Group (E1912). ASH 2018;Abstract LBA-4.
Sharman JP et al. ELEVATE TN: Phase 3 study of acalabrutinib combined with obinutuzumab (O) or alone vs O plus chlorambucil (Clb) in patients (Pts) with treatment-naive chronic lymphocytic leukemia (CLL). ASH 2019;Abstract 31.
Song Y et al. Zanubrutinib in patients with relapsed/refractory mantle cell lymphoma. ICML 2019;Abstract 015.
Straus DJ et al. Brentuximab vedotin with chemotherapy for stage 3/4 classical Hodgkin lymphoma: Three-year update of the ECHELON-1 study. ASCO 2019;Abstract 7532.
Tam CS et al. Updated safety and efficacy datain the phase 1 trial of patients with mantle cell lymphoma (MCL)treated with bruton tyrosinekinase (BTK) inhibitor zanubrutinib (BGB-3111). ICML 2019;Abstract 191.
Tam CS et al. Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma. N Engl J Med 2018;378(13):1211-23. Abstract
van der Stegen SJC et al. The pharmacology of second-generation chimeric antigen receptors. Nat Rev Drug Discov 2015;14(7):499-509. Abstract
Wang ML et al. KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in patients (Pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL): Results of the phase 2 ZUMA-2 study. ASH 2019;Abstract 754.
Wang M et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): A single-arm, multicentre, phase 2 trial. Lancet 2018;391(10121):659-67. Abstract
Wang M et al. Long-term follow-up of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma. ASH 2018;Abstract 2876.
Woyach JA et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med 2018;379(26):2517-28. Abstract
Younes A et al. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: A multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol 2016;17(9):1283-94. Abstract